Kynmobi

Apomorphine, the active ingredient in Kynmobi, is a dopamine agonist presented as a sublingual tablet for sublingual use. It treats OFF episodes in Parkinson's disease patients by rapidly restoring dopaminergic activity. GNH USA supplies Kynmobi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Apomorphine, a dopamine agonist used in Parkinson's disease, is indicated for managing OFF episodes and related motor fluctuations. - OFF episodes in Parkinson's disease: provides rapid reversal of motor symptoms during periods of reduced dopaminergic response. - Motor fluctuations in Parkinson's disease: improves on‑time and reduces periods of bradykinesia. - Adjunct therapy in Parkinson's disease: enhances overall dopaminergic control when combined with other antiparkinsonian agents.

Apomorphine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient feeling of sickness often occurring shortly after dosing. - Dizziness: light‑headedness that may be related to orthostatic changes. - Orthostatic hypotension: drop in blood pressure upon standing, leading to faintness. - Headache: mild to moderate pain often resolving with continued therapy. - Somnolence: increased sleepiness or fatigue during the day. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure decline requiring medical intervention. - Syncope: sudden loss of consciousness associated with blood‑pressure changes. - Hallucinations: visual or auditory disturbances that may affect safety. - Impulse‑control disorders: compulsive behaviors such as gambling or hypersexuality. - Cardiac arrhythmias: irregular heart rhythms that can be life‑threatening. - Persistent vomiting: prolonged emesis leading to dehydration and electrolyte imbalance.

When prescribing Kynmobi, clinicians should consider several safety measures. - Assess cardiovascular status: monitor blood pressure and heart rate before and during therapy. - Review concomitant medications: avoid co‑administration with MAO‑B inhibitors to prevent hypertensive crisis. - Evaluate for impulse‑control disorders: monitor patients for emerging compulsive behaviors. - Consider hepatic and renal function: adjust use in patients with significant impairment. - Avoid use in individuals with known hypersensitivity to apomorphine or excipients. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Apomorphine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis when combined. - Antipsychotics (D2 antagonists): may diminish apomorphine efficacy. - Other dopamine agonists: additive dopaminergic effects increasing side‑effect risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: potential enhancement of orthostatic hypotension. - SSRIs/SNRIs: may increase nausea and dizziness. - Alcohol: can amplify sedation and hypotensive effects.